Jiangxi Bio launches $60 million IPO, warns of sharp profit decline this year
Human tetanus antitoxin (TAT) maker Jiangxi Institute of Biological Products Inc. (6915.HK) launched its Hong Kong IPO on Monday, offering 36.23 million shares for HK$13.06 each to raise HK$473 million…
Recent Articles
RELATED ARTICLES
-
Wealth divide: Banks in China’s poorer regions bear brunt of margin squeeze
2139.HK1916.HK -
BRIEF: SolGold agrees to be acquired after Jiangxi Copper raises its bid price
0358.HK600362.SHG
-
Razor-thin margins slice holes in Leapmotor’s inaugural profit
9863.HK
-
BRIEF: Unisound launches third share placement this year to raise $48.6 million
9678.HK
-
BRIEF: Creality launches $177 million Hong Kong IPO
3388.HK
-
Longsys rides soaring memory wave to Hong Kong IPO
301308.SHE
- MSG giant Fufeng warns of potential first-half loss
